YMAB | Y-mAbs Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	13.27 - 14.27
52 Week Range	4.69 - 20.90
Beta	0.47
Implied Volatility	77.01%
IV Rank	8.55%
Day's Volume	313,337
Average Volume	282,067
Shares Outstanding	44,569,800
Market Cap	615,954,636
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-09-21

Valuation
Profitability
Growth
Health
P/E Ratio	-25.13
Forward P/E Ratio	-4.75
EPS	-0.55
1YR Price Target	23.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	100
Country	USA
Website	YMAB

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

YMAB's peers: BLUE, PMCB, TCRR, RVMD, BDTX, BCEL, PASG, MRSN, ZNTL, TVTX, GBIO, KRON, ERAS, CCCC, EWTX, ARQT, ICVX, MIRM, VECT, DAWN, PCVX, LRMR, SNDX, MRUS, STRO, ZYME

*Chart delayed

Analyzing fundamentals for YMAB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see YMAB Fundamentals page.

Watching at YMAB technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on YMAB Technicals page.